HET0016 attenuates the stemness of breast cancer cells through targeting CYP4Z1

Ours and other previous studies have shown that CYP4Z1 is specifically and highly expressed in breast Cancer, and acts as a promoter for the stemness of breast Cancer cells. Here, we explored whether targeting CYP4Z1 could attenuate the stemness of breast Cancer cells using HET0016, which has been confirmed to be an inhibitor of CYP4Z1 by us and Others. Using the transcriptome-sequencing analysis, we found that HET0016 suppressed the expression of Cancer stem cell (CSC) markers and stem cell functions. Additionally, HET0016 indeed reduced the stemness of breast Cancer cells, as evident by the decrease of stemness marker expression, CD44⁺ /CD24^- subpopulation with stemness, mammary-spheroid formation, and tumor-initiating ability. Moreover, HET0016 suppressed the metastatic capability through in vitro and in vivo experiments. Furthermore, we confirmed that HET0016 suppressed CYP4Z1 activity, and HET0016-induced inhibition on the stemness and metastasis of breast Cancer cells was rescued by CYP4Z1 overexpression. Thus, our results demonstrate that HET0016 can attenuate the stemness of breast Cancer cells through targeting CYP4Z1.